Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

• Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center
• Dr. Landau is a recognized thought leader in CAR-T cell therapy, bone marrow and solid organ transplantation and novel treatment approaches to plasma cell disorders including AL Amyloidosis and Multiple Myeloma

LOS ANGELES, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”) (Nasdaq:IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that Dr. Heather Landau has joined the Nexcella Scientific Advisory Board.  Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.

“Patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma deserve more effective treatments that can improve their outcomes,” said Dr. Landau. “Nexcella is leading development of a CAR-T in AL Amyloidosis with encouraging clinical results.  I am excited to join the Nexcella Scientific Advisory Board and help advance NXC-201 for U.S. patients with AL Amyloidosis and multiple myeloma.”

"We are delighted to have Dr. Landau join the Nexcella Scientific Advisory Board," stated Ilya Rachman, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added: “Dr. Landau’s wealth of experience comes from more than 15 years at MSK, with CAR-Ts and transplantation across indications to bring innovative treatment options to patients is inspirational.  We are excited to be collaborating with Dr. Landau.”

Dr. Heather Landau is the Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York. She has authored more than 100 peer-reviewed publications. Dr. Landau received her medical degree from SUNY Upstate Medical University, completed her Internal Medicine residency at University of Colorado and her Hematology & Oncology fellowship at Memorial Sloan Kettering Cancer Center. 

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology including CAR-T cell therapies and Tissue Specific Therapeutics (TSTx). Our lead CAR-T cell therapy asset, NXC-201, is being developed for relapsed/refractory AL Amyloidosis and relapsed/refractory multiple myeloma. Initial response rates of 92% and 100% have been observed from the Phase 1b/2a NEXICART-1 (NCT04720313) study in patients with multiple myeloma and AL amyloidosis (February 9, 2023). NXC-201 is being developed by ImmixBio’s subsidiary Nexcella, Inc and has the potential to be the world’s first out-patient CAR-T. Our lead Tissue Specific Therapeutic (TSTx) asset, IMX-110, is in Phase 1b/2a clinical trials as a monotherapy and in the IMMINENT-01 combination clinical trial with BeiGene’s anti-PD-1 antibody tislelizumab (NCT05840835). IMX-110 has been awarded Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the FDA. Learn more at www.immixbio.com.